Delivery Order SPE2DB25D3020-SPE2DB25FWJPT
- Not listed
- The Defense Logistics Agency awarded a $7,102.01 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract. The award, issued on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a non-competitive delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is located in Conshohocken, Pennsylvania, where the vendor maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 25, 2025, with a ceiling value of $27,476.51. The contract is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child contract issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,956.58 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This non-set-aside, firm fixed price delivery order was competitively awarded on August 8, 2025, with an ultimate completion date of August 11, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its corporate office location....
- The Defense Logistics Agency awarded a delivery order valued at $6,217.49 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-competitive set-aside delivery against an existing indefinite delivery contract. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a delivery order valued at $1,599.24 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 18, 2025, with completion scheduled for August 19, 2025. This non-competitive, firm fixed-price delivery order represents a continuation of the contractor's pharmaceutical supply relationship with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical...
- The Defense Logistics Agency awarded a $36,826.65 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 5, 2025. This delivery order represents a single...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,874.93 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order was not set-aside and represents a competitive award under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order valued at $13,322.71 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 6, 2025, with completion expected by August 7, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's pharmaceutical supply relationship with DLA. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $5,350.64 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 30, 2025, with a completion date of July 31, 2025. This firm fixed price delivery order represents a competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a delivery order valued at $1,599.24 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for completion by July 22, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement....
- SPE2DB25D3020Indefinite Delivery Contract
- SPE2DB25D3020-SPE2DB25FWJPTDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $7,367.25 to supply 30 tablets of XELJANZ XR 11 mg, a prescription pharmaceutical used to treat inflammatory conditions. Awarded on July 21, 2025, with completion scheduled for July 22, 2025, this is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The products will be delivered to Conshohocken, Pennsylvania, the vendor's corporate headquarters location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as the primary pharmaceutical supply vehicle for military healthcare systems worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor based in Conshohocken, Pennsylvania, regularly fulfills federal medical procurement requirements through its comprehensive product portfolio spanning brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities. The company's extensive federal contract history demonstrates its capability to meet open competition procurement standards and serve critical military and veteran healthcare needs through the DLA's Medical Supply Chain. The SPE2DX IDC enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs globally, including customers such as the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.4k | 7/21/25 |